Empagliflozin
| Evidence Level: L5 | Predicted Indications: 3 |
Table of Contents
Empagliflozin: Focal stiff limb syndrome
One-Sentence Summary
Empagliflozin is an SGLT2 inhibitor originally used to treat type 2 diabetes mellitus. The TxGNN model predicts it may be effective for focal stiff limb syndrome, but no clinical trials and no publications currently support this prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Focal stiff limb syndrome |
| TxGNN Prediction Score | 0.9906 |
| Evidence Level | L5 |
| Australia Market Status | Listed on the PBS Schedule (1 of 1 items) – TGA (ARTG) registration status is not included in this data |
| Number of PBS Items | 1 (valid: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Empagliflozin is known as an SGLT2 inhibitor that lowers blood glucose by reducing renal glucose reabsorption, and its efficacy in type 2 diabetes is established.
For focal stiff limb syndrome, no plausible mechanistic link has been identified. The condition belongs to the stiff-person spectrum, a neuro-immunological disorder involving impaired GABAergic or glycinergic inhibition, often with anti-GAD antibodies. SGLT2 inhibition has no known effect on this pathway.
The high score comes from the TxGNN model (deep learning) and may reflect similarities the model learned between related diseases, such as GAD autoimmunity and diabetes, not biological evidence. It should not be read as evidence of benefit.
Other predictions in the same list show a similar pattern. None has any clinical trial support.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for focal stiff limb syndrome.
Australia Market Information
| ARTG Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| ARTG 10202Y | Jardiance | Tablet 25 mg | Not available in the data compiled for this report |
Safety Considerations
- Drug Interactions: The interaction screen returned 100 potential interactions. Most of those listed are of moderate severity, and a few are minor. Examples include:
- Sympathomimetics and bronchodilators: phenylephrine, pseudoephedrine, epinephrine, salbutamol, formoterol
- Cardiovascular drugs: acebutolol, nifedipine, fosinopril, furosemide
- Other: acetazolamide, hydrocortisone, ethinylestradiol, ethanol, fosphenytoin, fosamprenavir
Minor interactions were listed for topical corticosteroids (hydrocortisone, alclometasone).
For warnings and contraindications, please refer to the TGA-approved Product Information (PI).
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction has no supporting trials or publications and no plausible mechanistic link. It is likely a TxGNN model (deep learning) artefact linked to GAD autoimmunity and diabetes. The evidence level is L5 (model prediction only).
To proceed, the following is needed:
- Mechanism of action data and a credible biological rationale linking SGLT2 inhibition to the stiff-person spectrum
- Preclinical or clinical evidence in focal stiff limb syndrome (none currently exists)
- Review of the TGA-approved Product Information for warnings and contraindications
- Approved indication text for the Australian ARTG entry
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.